Clinical trial
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
NCT02192554 is registered in ClinicalTrials.gov with Otsuka Pharmaceutical Development & Commercialization, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Phase
- Observational
- Overall status
- Completed
- Start date
- June 30, 2014
- Completion date
- May 31, 2017
- Enrollment
- 450 (actual)
- Sites
- 84
Conditions
As the registry lists them; a condition with its own page is linked.
agitation associated with alzheimer's disease, alzheimer's type, mental disorder, nervous system diseases